Abstract
The incidence of bladder cancer varies substantially between different geographic regions, which can in part be attributed to regional differences in exposures, although differences in reporting may also play a role. In general, the incidence tends to be higher in developed countries than less developed ones. In all geographic regions, men are much more likely to be diagnosed with bladder cancer than women, and within each sex the risk of bladder cancer diagnosis increases considerably with age. Smoking remains the most important known modifiable risk factors for bladder cancer development, although other occupational and environmental exposures exist.
The true natural history of untreated bladder cancer is not known because the disease is almost always discovered during the patient’s lifetime, most frequently due to hematuria, and is treated at least by transurethral resection. The natural history of treated bladder cancer (i.e., the expected clinical course) is highly variable, depending on tumor characteristics at presentation. On the one side of the spectrum are the low-grade urothelial cancers confined to the bladder surface which, despite frequent local recurrences, rarely progress and typically do not pose a threat to a patient’s life. On the other side are the high-grade muscle-invasive lesions that often produce early metastases and cause death despite aggressive treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr.
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
American Cancer Society. Bladder cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Accessed 3 June 2013.
Alberg AJ, Kouzis A, Genkinger JM, et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol. 2007;165(6):660–6.
Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol. 1993;3(3):211–21.
Mills PK, Beeson WL, Phillips RL, Fraser GE. Bladder cancer in a low risk population: results from the Adventist Health Study. Am J Epidemiol. 1991;133(3):230–9.
Tripathi A, Folsom AR, Anderson AE, Iowa Women’s Health Study. Risk factors for urinary bladder carcinoma in postmenopausal women. Cancer. 2002;95(11):2316–23.
Michaud DS, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology. 2001;12(6):719–26.
Cantwell MM, Lacey Jr JV, Schairer C, Schatzkin A, Michaud DS. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer. 2006;119(10):2398–401.
Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45.
Bartsch H, et al. Black (air cured) and blond (flue-cured) tobacco cancer risk. IV. Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer. 1993;29:1199–208.
Bernardini S, et al. Influence of cigarette smoking on p53 gene mutations in bladder carcinomas. Anticancer Res. 2001;21:3001–4.
Risch A, Wallace DM, Bathers S, et al. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995;4(2):231–6.
Cui X, Lu X, Hiura M, Omori H, Miyazaki W, Katoh T. Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med. 2013;18(2):136–42.
Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85(14):1159–64.
GarcĂa-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, TardĂ³n A, Serra C, Carrato A, GarcĂa-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, TorĂ M, FernĂ¡ndez F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–59.
Van Hemelrijck MJ, Michaud DS, Connolly GN, Kabir Z. Secondhand smoking, 4-aminobiphenyl, and bladder cancer: two meta-analyses. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1312–20.
Verma DK, Purdham JT, Roels HA. Translating evidence about occupational conditions into strategies for prevention. Occup Environ Med. 2002;59:205–14.
Markowitz SB, Levin K. Continued epidemic of bladder cancer in workers exposed to ortho-toluidine in a chemical factory. J Occup Environ Med. 2004;46:154–60.
Rushton L, Hutchings SJ, Fortunato L, Young C, Evans GS, Brown T, Bevan R, Slack R, Holmes P, Bagga S, Cherrie JW, Van Tongeren M. Occupational cancer burden in Great Britain. Br J Cancer. 2012;107 Suppl 1:S3–7.
Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68–74.
Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS, Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007;51(3):699–706.
Resorlu B, Beduk Y, Baltaci S, Ergun G, Talas H. The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy. BJU Int. 2009;103(4):480–3.
Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP. Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database. Urol Oncol. 2012;30(6):825–32.
Fiore MC, Novotny TE, Pierce JP, et al. Trends in cigarette smoking in the US: the changing influence of gender and race. JAMA. 1989;261:49–55.
Donsky H, Coyle S, Scosyrev E, Messing EM. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol Oncol. 2014;32:40.e23–31.
Hartge P, Harvey EB, Linehan WB, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82:1636–40.
Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–68.
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109(11):1716–26.
Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, Pike MC, Bernstein L, Cortessis VK. Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1156–70.
Dietrich K, Demidenko E, Schned A, Zens MS, Heaney J, Karagas MR. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer. 2011;47(4):592–9.
Scosyrev E, Trivedi D, Messing E. Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol. 2010;20:404–8.
Scosyrev E, Golijanin D, Wu G, Messing EM. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. 2012;109(1):57–62.
Horstmann M, Witthuhn R, Falk M, et al. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med. 2008;5:385–94.
Tilki D, Svatek RS, Karakiewicz PL, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010;187:87–93.
Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012;62(1):118–25.
Kirkali Z, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.
StiborovĂ¡ M, MartĂnek V, Frei E, Arlt VM, Schmeiser HH. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab. 2013;14:695–705.
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30:1026–32. doi:10.1111/dme.12144.
Kumar S, Shah JP, Bryant CS, et al. Second neoplasms in survivors of endometrial cancer: impact of radiation therapy. Gynecol Oncol. 2009;113:233–9.
Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys. 2010;78:127–35.
Lonn S, Gilbert ES, Ron E, Smith SA, Stovall M, Curtis RE. Comparison of second cancer risks from brachytherapy and external beam radiation therapy after uterine corpus cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:464–74.
Abern MR, Dude AM, Tsivian M, Coogan CL. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol. 2012;31:1628–34.
Kukreja B, Scosyrev E, Brasacchio R, Toy E, Messing E, Wu G. Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. Abstract presented at AUA 2013.
Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 2009;73(4):822–7.
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry Jr CP, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–22.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.
Borhan A, Reeder JE, O'’onnell MJ, Wright KO, Wheeless LL, di Sant’Agnese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. J Urol. 2003;169(6):2106–9.
Aldousari S, Kassouf W. Update on the management of non-muscle-invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64.
Babjuk M, Oosterlinck W, Sylvester R, et al. Guidelines on non-muscle-invasive bladder cancer. European Association of Urology 2012. http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer.pdf. Accessed 3 May 2013.
Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013;111:1215–21. doi:10.1111/j.1464-410X.2012.11455.x.
Compérat E, Jacquet SF, Varinot J, Conort P, Roupret M, Chartier-Kastler E, Bitker MO, Witjes JA, Cussenot O. Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. Virchows Arch. 2013;462(3):343–8.
Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19(3):499–508.
Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–6.
Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490–3.
Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117–22.
Von Der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.
Clark PE, Agarwal N, Biagioli MC, et al. NCCN clinical practice guideline in oncology: bladder cancer. Version I. 2013. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 3 June 2013
Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG. Neo-adjuvant gemcitabine-cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 2012;118(1):72–81.
Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int. 2013;111(3):404–11. doi:10.1111/j.1464-410X.2012.11370.x. Epub 2012 Jul 13.
Power NE, Kassouf W, Bell D, et al. Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-american multi-institutional cohort. Can Urol Assoc J. 2012;6(6):E217–23.
Turker P, Bostrom PJ, Wroclawski ML, van Rhijn B, Kortekangas H, Kuk C, Mirtti T, Fleshner NE, Jewett MA, Finelli A, Kwast TV, Evans A, Sweet J, Laato M, Zlotta AR. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int. 2012;110(6):804–11.
Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119:3012–9. doi: 10.1002/cncr.28146. [Epub ahead of print].
Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, Sjoberg D, Dalbagni G, Bochner BH. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012;61(5):1025–30.
Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9.
Scosyrev E, Yao J, Messing E. Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology. 2010;76(4):908–13.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:189–201. Discussion 199–201.
Herr HW, Donat SM. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol. 2001;165(1):62–4. Discussion 64.
Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013;pii: S0302-2838(13): 0042–-1. doi: 10.1016/j.eururo.2013.04.036. [Epub ahead of print]
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood Jr DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.
Yuh BE, Ruel N, Wilson TG, et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol. 2013;189:1682–6.
Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, Daneshmand S, Skinner EC, Skinner DG. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174(1):103–6.
D'Souza AM, Pohar KS, Arif T, Geyer S, Zynger DL. Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Arch. 2012;461(4):467–74.
Gondo T, Nakashima J, Ozu C, Ohno Y, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M. Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy. Int J Clin Oncol. 2012;17(5):456–61.
Palmieri F, Brunocilla E, Bertaccini A, Guidi M, Pernetti R, Morselli-Labate AM, Martorana G. Prognostic value of lymphovascular invasion in bladder cancer in patients treated with radical cystectomy. Anticancer Res. 2010;30(7):2973–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Messing, E., Scosyrev, E. (2015). Epidemiology and Natural History. In: Konety, B., Chang, S. (eds) Management of Bladder Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1881-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1881-2_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1880-5
Online ISBN: 978-1-4939-1881-2
eBook Packages: MedicineMedicine (R0)